Latest News

CLINUVEL Pharmaceuticals (ASX:CUV) has taken a significant step toward expanding its product portfolio, confirming it is planning to lodge a European regulatory submission for its second pharmaceutical product, NEURACTHEL Instant, by mid-2026.

Imugene (ASX:IMU) has released new clinical data showing an 82 per cent overall response rate in its Phase 1b trial of azer-cel, the company’s allogeneic, off-the-shelf CD19 CAR T therapy for patients with relapsed or refractory diffuse large B-cell lymphoma.

Tetratherix (ASX:TTX) has announced a significant step forward for its US-based joint venture BioOptix, with the ophthalmic biomaterials company signing a development agreement with global eye-care leader Alcon Research.

Melbourne is putting its biomedical and health innovation ecosystem on display as delegates from across Australia and overseas gather in the city for the National Health and Innovation Precincts Summit, the first time the annual event has been hosted in Victoria.

Cartherics has announced a significant leadership transition, appointing biotechnology executive and company co-founder Dr Ian Nisbet as Chief Executive Officer as the Melbourne-based cell therapy developer prepares for its next phase of growth.

Immutep (ASX:IMM) will present new clinical results from its AIPAC-003 Phase 2 trial at next week’s San Antonio Breast Cancer Symposium, highlighting encouraging response rates and clear signs of immune activation in heavily pretreated metastatic breast cancer patients.

Entropy Neurodynamics (ASX:ENP) has marked a significant clinical milestone, successfully administering the first dose of its proprietary psilocin formulation, TRP-8803, in a trial targeting binge eating disorder.

Chimeric Therapeutics (ASX:CHM) has reassured investors of its strategic direction and clinical momentum, announcing a forthcoming refresh of its board and reaffirming backing from major shareholders following its Annual General Meeting held on 25 November.

AusBiotech is pleased to share an opportunity for Australia’s life sciences community to hear directly from AstraZeneca’s global Search and Evaluation leaders.

The agreement brings together Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s CD19-directed autologous CAR-T therapy, Carteyva, in a program that spans preclinical studies through to a Phase 1 investigator-initiated clinical trial in China.

Neurizon Therapeutics (ASX:NUZ) Chair Sergio Duchini has told shareholders the company is entering a decisive phase in its mission to bring new treatments to patients with neurodegenerative diseases, describing the past year as one of disciplined execution, strengthened governance, and meaningful scientific progress.

Proteomics International (ASX:PIQ) has secured a significant milestone in its push into the US healthcare market, with Medicare authorities setting a national reimbursement price of US$390.75 for its PromarkerD test, a predictive diagnostic for diabetic kidney disease.